Results 201 to 210 of about 86,509 (340)

Fatal Hepatitis B Reactivation in Absence of Antibody to Hepatitis B Core Antigen in a Lymphoma Patient

Journal of Medical Virology, Volume 97, Issue 7, July 2025.
ABSTRACT Reactivations of hepatitis B virus (HBV) infection in severely immunocompromised patients with serological profiles of past hepatitis B are non‐exceptional and potentially severe or fatal events. The preventive and pre‐emptive detection of this serological status is compromised in the absence of antibodies to hepatitis B core antigen (anti‐HBc)
Solenn Klutsch, Céline Boschi, Anne Motte, Philippe Halfon, Patrick Borentain, René Gerolami, Philippe Colson   +6 more
wiley   +1 more source

Varicella-Zoster Virus and Subcutaneous Cytarabine: Correlation of In Vitro Sensitivities to Blood Levels

, 1975
Dawlat A. Zaky, Robert F. Betts, R. Gordon Douglas, Kathleen Bengali, G L Neil   +4 more
openalex   +1 more source

Interdisciplinary Approach to Monkeypox Prevention: Integrating Nanobiosensors, Nanovaccines, Artificial Intelligence, Visual Arts, and Social Sciences

Small Structures, Volume 6, Issue 7, July 2025.
This illustration depicts a comprehensive strategy against monkeypox, showcasing its transmission, symptoms, and prevention. Centralized around nanomaterials and biosensors, it integrates early screening, Internet of Things, vaccination, and community involvement through collaboration among healthcare workers, scientists, researchers, social groups ...
Vishal Chaudhary, Lucky Lucky, Harsh Sable, Nikhil Bhalla   +3 more
wiley   +1 more source

Varicella-Zoster Virus Immunizes Patas Monkeys against Simian Varicella-like Disease

, 1979
A. D. Felsenfeld, Nathalie J. Schmidt
openalex   +1 more source

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 7, Page 1336-1351, July 2025.
In this analysis of the long‐term safety and efficacy of deucravacitinib in patients with moderate to severe plaque psoriasis treated through 4 years, no new safety signals were observed compared with the first year. Patients continuously treated with deucravacitinib from Day 1 maintained clinical and patient‐reported outcome response rates.
April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimichi Morita, Carle Paul, Kim A. Papp, Matthew J. Colombo, Julie Scotto, John Vaile, Joe Zhuo, Eleni Vritzali, Victoria Berger, Georgene Schroeder, Subhashis Banerjee, Diamant Thaçi, Bruce Strober   +16 more
wiley   +1 more source

New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products [PDF]

, 1986
Andrew J. Davison, C M Edson, Ronald W. Ellis, Bagher Forghani, Donald H. Gilden, Charles Grose, Paul M. Keller, Abbas Vafai, Zofia Wróblewska, K Yamanishi   +9 more
openalex   +1 more source

The production of varicella zoster virus antiserum in laboratory animals [PDF]

, 1982
Zofia Wróblewska, Mary Devlin, Kristen Reilly, H. van Trieste, Mary Wellish, Donald H. Gilden   +5 more
openalex   +1 more source

Varicella-zoster virus complements herpes simplex virus type 1 temperature-sensitive mutants [PDF]

, 1987
James M. Felser, Stephen E. Straus, Jeffrey M. Ostrove   +2 more
openalex   +1 more source

A systematic review and meta-analysis of Seroprevalence of Varicella Zoster virus : a nationwide population-based study [PDF]

, 2016
Amjadi, Omolbanin, Arabi, Mohsen, Ashrafi, G. Hossein, Haghshenas, Mohammadreza, Hosseini-Khah, Zahra, Mousavi, Tahoora, Navaei, Reza Alizadeh, Omran, Akbar Hedayatizadeh, Rafiei, Alireza, Shakib, Reza Jafari, Valadan, Reza   +10 more
core   +1 more source

A Diagnostic Challenge: Varicella-Zoster Virus Meningoencephalitis in a Young Medical Student. [PDF]

Cureus
Zatoulovski M, de Castro J, Tashpulatova Z, Legradi G.   +3 more
europepmc   +1 more source